2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistry
2006
Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism.
Agarwal R, Gulati M, Mittal B, Jindal S. Clinical profile, diagnosis and management of patients presenting with symptomatic pulmonary embolism. The Indian Journal Of Chest Diseases & Allied Sciences 2006, 48: 111-4. PMID: 16696525.Peer-Reviewed Original ResearchConceptsSymptomatic pulmonary embolismPulmonary embolismClinical profileLow molecular weight heparinOutcomes of patientsPulmonary artery hypertensionManagement of patientsMolecular weight heparinArtery hypertensionVentricular dyskinesiaAggressive managementClinical featuresPredominant complaintWeight heparinPerfusion scanMean ageEarly diagnosisProspective assessmentPatientsEmbolismSuccessful outcomeStudy periodDiagnostic methodsDiagnosisOutcomes